表紙
市場調査レポート

BeiGene (Beijing) Co., Ltdの製品パイプライン分析

BeiGene(Beijing) Co.,Ltd - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 319964
出版日 ページ情報 英文 36 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
BeiGene (Beijing) Co., Ltdの製品パイプライン分析 BeiGene(Beijing) Co.,Ltd - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 36 Pages
概要

BeiGene (Beijing) Co., Ltdは中国に本社を置くバイオ製薬企業です。様々な癌の症状に対するアンメットニーズを対象とした腫瘍免疫薬の創薬・開発、および薬剤候補物質を同定するための様々な研究を行っています。

当レポートでは、BeiGene (Beijing) Co., Ltd における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

BeiGene (Beijing) Co., Ltd の基本情報

  • BeiGene (Beijing) Co., Ltd の概要
  • 主要情報
  • 企業情報

BeiGene (Beijing) Co., Ltd :R&Dの概要

  • 主な治療範囲

BeiGene (Beijing) Co., Ltd :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

BeiGene (Beijing) Co., Ltd :パイプライン製品の概況

  • 臨床段階にあるパイプライン製品
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ
    • 創薬段階の製品/併用療法モダリティ

BeiGene (Beijing) Co., Ltd :薬剤プロファイル

  • BeiGene-290
  • BGB-102
  • BGB-283
  • BGB-3111
  • Monoclonal Antibody to Inhibit PD-1 for Cancer
  • Monoclonal Antibody for Cancer
  • Monoclonal Antibody to Inhibit PD-L1 for Cancer
  • Small Molecule 1 for Oncology
  • Small Molecule to Inhibit BRD4 for Cancer
  • Small Molecule to Inhibit EGFR for Cancer

BeiGene (Beijing) Co., Ltd :パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

BeiGene (Beijing) Co., Ltd :開発休止中のプロジェクト

BeiGene (Beijing) Co., Ltd :本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07893CDB

Summary

Global Markets Direct's, 'BeiGene(Beijing) Co.,Ltd - Product Pipeline Review - 2015', provides an overview of the BeiGene(Beijing) Co.,Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BeiGene(Beijing) Co.,Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of BeiGene(Beijing) Co.,Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of BeiGene(Beijing) Co.,Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the BeiGene(Beijing) Co.,Ltd's pipeline products

Reasons to buy

  • Evaluate BeiGene(Beijing) Co.,Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of BeiGene(Beijing) Co.,Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the BeiGene(Beijing) Co.,Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of BeiGene(Beijing) Co.,Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of BeiGene(Beijing) Co.,Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of BeiGene(Beijing) Co.,Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • BeiGene(Beijing) Co.,Ltd Snapshot
    • BeiGene(Beijing) Co.,Ltd Overview
    • Key Information
    • Key Facts
  • BeiGene(Beijing) Co.,Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • BeiGene(Beijing) Co.,Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • BeiGene(Beijing) Co.,Ltd - Pipeline Products Glance
    • BeiGene(Beijing) Co.,Ltd - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • BeiGene(Beijing) Co.,Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • BeiGene(Beijing) Co.,Ltd - Drug Profiles
    • BGB-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-283
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-290
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-3111
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGBA-317
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-108
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit PD-L1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize Smoothened (Smo) Receptor for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • BeiGene(Beijing) Co.,Ltd - Pipeline Analysis
    • BeiGene(Beijing) Co.,Ltd - Pipeline Products by Target
    • BeiGene(Beijing) Co.,Ltd - Pipeline Products by Route of Administration
    • BeiGene(Beijing) Co.,Ltd - Pipeline Products by Molecule Type
    • BeiGene(Beijing) Co.,Ltd - Pipeline Products by Mechanism of Action
  • BeiGene(Beijing) Co.,Ltd - Recent Pipeline Updates
  • BeiGene(Beijing) Co.,Ltd - Dormant Projects
  • BeiGene(Beijing) Co.,Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • BeiGene(Beijing) Co.,Ltd, Key Information
  • BeiGene(Beijing) Co.,Ltd, Key Facts
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Indication, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Stage of Development, 2015
  • BeiGene(Beijing) Co.,Ltd - Monotherapy Products in Pipeline, 2015
  • BeiGene(Beijing) Co.,Ltd - Phase I, 2015
  • BeiGene(Beijing) Co.,Ltd - Preclinical, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Target, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Route of Administration, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Molecule Type, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline Products by Mechanism of Action, 2015
  • BeiGene(Beijing) Co.,Ltd - Recent Pipeline Updates, 2015
  • BeiGene(Beijing) Co.,Ltd - Dormant Developmental Projects,2015

List of Figures

  • BeiGene(Beijing) Co.,Ltd - Pipeline by Top 10 Indication, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Stage of Development, 2015
  • BeiGene(Beijing) Co.,Ltd - Monotherapy Products in Pipeline, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Top 10 Target, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline by Top 10 Molecule Type, 2015
  • BeiGene(Beijing) Co.,Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top